Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Employees are getting better at saving into HSAs but they’re leaving money on the table by not investing it.
The State Street SPDR S&P Biotech ETF is up 33% this year, but fund flows remain muted.
Consider the dream of the presumptively dovish Warsh delivering a rate cut this year now officially dead and buried (if it wasn’t already)
There’s an increasing amount of scientific evidence pointing to the importance of good sleep hygiene for cognitive health in retirement.
The right choice depends on client preferences about cost predictability and risk management.
Federal grants have helped keep Medicare Part D prescription drug costs down, but they’re set to end next year.
The projection is up 7.5% from last year, and marks the largest annual jump in more than a decade, according to a new Fidelity study.
They can result in many thousands of dollars in excess costs and even jeopardize access to care in the worst cases.
Psychedelic medications, backed by the White House, may alter the prognosis for people with treatment-resistant depression, but risks remain.
Labor-intensive services such as gardening, home healthcare and day care and preschool were all significant drivers of inflation.
Retirement planning is much more dynamic than a decade ago, and financial advisors are rewriting the playbook.
The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly’s recently published study.
Evercore ISI analysts said in a note they “see no meaningful revenue opportunity” for Moderna in hantaviruses.
A recent rule change requiring higher earners to use Roth accounts for catch-up contributions has some adopting a different strategy.
Scary stats about the cost of health care in retirement drive many to simply ignore the issue, resulting in missed planning opportunities.